Denmark · Delayed Price · Currency is DKK Pharma Equity Group Earnings Call Transcripts
Fiscal Year 2024
-
A capital reduction and subsequent increase enabled a DKK 51 million raise, reducing debt by DKK 38.5 million and diluting shareholders by 17%. Focus is on securing further funding, advancing clinical studies, and finalizing a licensing deal by late 2025.
-
Positive clinical progress and strategic focus on licensing and capital structure mark the half-year, with increased costs due to organizational growth and a maintained loss guidance of DKK 24–29 million. A capital increase is planned with minimal expected dilution.
-
A new commercial relationship director is leading efforts to expand clinical and industry networks, conduct in-depth market analysis, and identify strategic partners with financial and development strength. The goal is to secure the first partnership in 2025, with flexible agreement structures and a global focus.